Novo Nordisk Rises 6% So Far in August: How to Play the Stock

Novo Nordisk (NVO) shares gained 5.8% in August, staging a recovery despite prior guidance cuts and competitive headwinds. This rebound was largely driven by Eli Lilly's major pipeline setback with its oral GLP-1 candidate, orforglipron, which exhibited underwhelming efficacy and high discontinuation rates, shifting investor sentiment. This presents a significant opportunity for NVO, particularly with potential FDA approval for its 25 mg oral semaglutide for obesity by year-end, which could establish it as the sole provider of a marketed oral obesity pill, enhancing adherence and market share. Coupled with strong Wegovy sales ($5.41B H1 2025, +78% YoY) and a robust pipeline including next-generation candidates like CagriSema and Amycretin, NVO is well-positioned to capitalize on the expanding $100 billion obesity market, affirming its long-term strategic strength despite ongoing competitive dynamics and initial uptake challenges.

Analysis

Novo Nordisk is experiencing a significant positive shift in market sentiment, reflected in a 5.8% share price gain in August, primarily catalyzed by a strategic setback for its chief rival, Eli Lilly. Lilly's oral GLP-1 candidate, orforglipron, reported underwhelming efficacy and high patient discontinuation rates, diminishing its immediate competitive threat and redirecting investor focus to NVO's strengths. This comes after NVO itself faced headwinds, including a July guidance cut for 2025 sales and profit growth, and slower-than-expected uptake of its key obesity drug, Wegovy, due to competition and counterfeit sales. Despite these challenges, NVO's fundamentals remain robust; Wegovy sales grew 78% year-over-year to $5.41 billion in the first half of 2025, and the company maintains a superior return on equity of 78.64% compared to the industry's 34.32%. A key near-term catalyst is the potential year-end FDA approval for a 25 mg oral semaglutide, which would give NVO a first-to-market advantage in the oral obesity segment. While the stock has underperformed year-to-date, its forward P/E of 12.12 is below its historical average and the industry's, and earnings estimates for 2025 and 2026 have seen recent upward revisions. The company's long-term outlook is further supported by a deep pipeline featuring next-generation assets like CagriSema and Amycretin, positioning it to compete effectively in the projected $100 billion obesity market.

Key Decisions for Investors

• Given the stock's 42.1% year-to-date decline and a valuation below historical and industry averages, long-term investors may view the current price as a strategic entry point, capitalizing on the improved competitive landscape following Eli Lilly's pipeline setback.
• Investors should closely monitor the FDA's decision on the 25 mg oral semaglutide expected by year-end, as an approval would be a significant positive catalyst, solidifying a first-mover advantage in the oral obesity market.
• It is prudent to continue monitoring near-term risks, including the pace of international Wegovy uptake, the impact of counterfeit drug litigation, and the clinical progress of competitors like Amgen and Viking Therapeutics, which may introduce volatility.
• The combination of strong revenue growth from existing GLP-1 franchises, a promising next-generation pipeline, and a key competitor's stumble suggests that current holders should consider maintaining their positions despite recent share price underperformance.